Incidentally, there were also positive correlations between high mean expression of JAM-A and HER2 and either recurrence-free survival (RFS) or overall survival (OS) in HER2-positive breast cancer patients; however, due to relatively small sample numbers with available genomic data on kmplot.com (882 patients for RFS, 420 patients for OS), these observations did not reach statistical significance (p = 0.05 for RFS and p = 0.12 for OS; data not shown). The gene discussed is ERBB2; the disease is breast carcinoma.